Acquisition of C3d-Binding Activity by De Novo Donor-Specific HLA Antibodies Correlates With Graft Loss in Nonsensitized Pediatric Kidney Recipients

Patrizia Comoli, M. Cioni, A. Tagliamacco, Giuseppe Quartuccio, A. Innocente, I. Fontana, Antonella Trivelli, Alberto Magnasco, Angela Nocco, Catherine Klersy, Laura Rubert, Miriam Ramondetta, Marco Zecca, G. Garibotto, Gian Marco Ghiggeri, Massimo Cardillo, A. Nocera, F. Ginevri

Research output: Contribution to journalArticle

Abstract

Alloantibody-mediated graft injury is a major cause of kidney dysfunction and loss. The complement-binding ability of de novo donor-specific antibodies (dnDSAs) has been suggested as a prognostic tool to stratify patients for clinical risk. In this study, we analyzed posttransplant kinetics of complement-fixing dnDSAs and their role in antibody-mediated rejection development and graft loss. A total of 114 pediatric nonsensitized recipients of first kidney allograft were periodically monitored for dnDSAs using flow bead assays, followed by C3d and C1q assay in case of positivity. Overall, 39 patients developed dnDSAs, which were C1q+ and C3d+ in 25 and nine patients, respectively. At follow-up, progressive acquisition over time of dnDSA C1q and C3d binding ability, within the same antigenic specificity, was observed, paralleled by an increase in mean fluorescence intensity that correlated with clinical outcome. C3d-fixing dnDSAs were better fit to stratify graft loss risk when the different dnDSA categories were evaluated in combined models because the 10-year graft survival probability was lower in patients with C3d-binding dnDSA than in those without dnDSAs or with C1q+/C3d or non-complement-binding dnDSAs (40% vs. 94%, 100%, and 100%, respectively). Based on the kinetics profile, we favor dnDSA removal or modulation at first confirmed positivity, with treatment intensification guided by dnDSA biological characteristics.

Original languageEnglish
Pages (from-to)2106-2116
Number of pages11
JournalAmerican Journal of Transplantation
Volume16
Issue number7
DOIs
Publication statusPublished - Jul 1 2016

Fingerprint

Tissue Donors
Pediatrics
Transplants
Kidney
Antibodies
Isoantibodies
Graft Rejection
Graft Survival
Allografts
Epitopes
Fluorescence
Wounds and Injuries

Keywords

  • alloantibody
  • clinical research/practice
  • immunobiology
  • immunosuppression/immune modulation
  • kidney (allograft) function/dysfunction
  • kidney transplantation/nephrology
  • monitoring: immune
  • rejection: antibody-mediated (ABMR)

ASJC Scopus subject areas

  • Transplantation
  • Immunology and Allergy
  • Pharmacology (medical)

Cite this

Acquisition of C3d-Binding Activity by De Novo Donor-Specific HLA Antibodies Correlates With Graft Loss in Nonsensitized Pediatric Kidney Recipients. / Comoli, Patrizia; Cioni, M.; Tagliamacco, A.; Quartuccio, Giuseppe; Innocente, A.; Fontana, I.; Trivelli, Antonella; Magnasco, Alberto; Nocco, Angela; Klersy, Catherine; Rubert, Laura; Ramondetta, Miriam; Zecca, Marco; Garibotto, G.; Ghiggeri, Gian Marco; Cardillo, Massimo; Nocera, A.; Ginevri, F.

In: American Journal of Transplantation, Vol. 16, No. 7, 01.07.2016, p. 2106-2116.

Research output: Contribution to journalArticle

Comoli, P, Cioni, M, Tagliamacco, A, Quartuccio, G, Innocente, A, Fontana, I, Trivelli, A, Magnasco, A, Nocco, A, Klersy, C, Rubert, L, Ramondetta, M, Zecca, M, Garibotto, G, Ghiggeri, GM, Cardillo, M, Nocera, A & Ginevri, F 2016, 'Acquisition of C3d-Binding Activity by De Novo Donor-Specific HLA Antibodies Correlates With Graft Loss in Nonsensitized Pediatric Kidney Recipients', American Journal of Transplantation, vol. 16, no. 7, pp. 2106-2116. https://doi.org/10.1111/ajt.13700
Comoli, Patrizia ; Cioni, M. ; Tagliamacco, A. ; Quartuccio, Giuseppe ; Innocente, A. ; Fontana, I. ; Trivelli, Antonella ; Magnasco, Alberto ; Nocco, Angela ; Klersy, Catherine ; Rubert, Laura ; Ramondetta, Miriam ; Zecca, Marco ; Garibotto, G. ; Ghiggeri, Gian Marco ; Cardillo, Massimo ; Nocera, A. ; Ginevri, F. / Acquisition of C3d-Binding Activity by De Novo Donor-Specific HLA Antibodies Correlates With Graft Loss in Nonsensitized Pediatric Kidney Recipients. In: American Journal of Transplantation. 2016 ; Vol. 16, No. 7. pp. 2106-2116.
@article{2fa3aa90bfc645768b719dc65d95b626,
title = "Acquisition of C3d-Binding Activity by De Novo Donor-Specific HLA Antibodies Correlates With Graft Loss in Nonsensitized Pediatric Kidney Recipients",
abstract = "Alloantibody-mediated graft injury is a major cause of kidney dysfunction and loss. The complement-binding ability of de novo donor-specific antibodies (dnDSAs) has been suggested as a prognostic tool to stratify patients for clinical risk. In this study, we analyzed posttransplant kinetics of complement-fixing dnDSAs and their role in antibody-mediated rejection development and graft loss. A total of 114 pediatric nonsensitized recipients of first kidney allograft were periodically monitored for dnDSAs using flow bead assays, followed by C3d and C1q assay in case of positivity. Overall, 39 patients developed dnDSAs, which were C1q+ and C3d+ in 25 and nine patients, respectively. At follow-up, progressive acquisition over time of dnDSA C1q and C3d binding ability, within the same antigenic specificity, was observed, paralleled by an increase in mean fluorescence intensity that correlated with clinical outcome. C3d-fixing dnDSAs were better fit to stratify graft loss risk when the different dnDSA categories were evaluated in combined models because the 10-year graft survival probability was lower in patients with C3d-binding dnDSA than in those without dnDSAs or with C1q+/C3d− or non-complement-binding dnDSAs (40{\%} vs. 94{\%}, 100{\%}, and 100{\%}, respectively). Based on the kinetics profile, we favor dnDSA removal or modulation at first confirmed positivity, with treatment intensification guided by dnDSA biological characteristics.",
keywords = "alloantibody, clinical research/practice, immunobiology, immunosuppression/immune modulation, kidney (allograft) function/dysfunction, kidney transplantation/nephrology, monitoring: immune, rejection: antibody-mediated (ABMR)",
author = "Patrizia Comoli and M. Cioni and A. Tagliamacco and Giuseppe Quartuccio and A. Innocente and I. Fontana and Antonella Trivelli and Alberto Magnasco and Angela Nocco and Catherine Klersy and Laura Rubert and Miriam Ramondetta and Marco Zecca and G. Garibotto and Ghiggeri, {Gian Marco} and Massimo Cardillo and A. Nocera and F. Ginevri",
year = "2016",
month = "7",
day = "1",
doi = "10.1111/ajt.13700",
language = "English",
volume = "16",
pages = "2106--2116",
journal = "American Journal of Transplantation",
issn = "1600-6135",
publisher = "Wiley-Blackwell",
number = "7",

}

TY - JOUR

T1 - Acquisition of C3d-Binding Activity by De Novo Donor-Specific HLA Antibodies Correlates With Graft Loss in Nonsensitized Pediatric Kidney Recipients

AU - Comoli, Patrizia

AU - Cioni, M.

AU - Tagliamacco, A.

AU - Quartuccio, Giuseppe

AU - Innocente, A.

AU - Fontana, I.

AU - Trivelli, Antonella

AU - Magnasco, Alberto

AU - Nocco, Angela

AU - Klersy, Catherine

AU - Rubert, Laura

AU - Ramondetta, Miriam

AU - Zecca, Marco

AU - Garibotto, G.

AU - Ghiggeri, Gian Marco

AU - Cardillo, Massimo

AU - Nocera, A.

AU - Ginevri, F.

PY - 2016/7/1

Y1 - 2016/7/1

N2 - Alloantibody-mediated graft injury is a major cause of kidney dysfunction and loss. The complement-binding ability of de novo donor-specific antibodies (dnDSAs) has been suggested as a prognostic tool to stratify patients for clinical risk. In this study, we analyzed posttransplant kinetics of complement-fixing dnDSAs and their role in antibody-mediated rejection development and graft loss. A total of 114 pediatric nonsensitized recipients of first kidney allograft were periodically monitored for dnDSAs using flow bead assays, followed by C3d and C1q assay in case of positivity. Overall, 39 patients developed dnDSAs, which were C1q+ and C3d+ in 25 and nine patients, respectively. At follow-up, progressive acquisition over time of dnDSA C1q and C3d binding ability, within the same antigenic specificity, was observed, paralleled by an increase in mean fluorescence intensity that correlated with clinical outcome. C3d-fixing dnDSAs were better fit to stratify graft loss risk when the different dnDSA categories were evaluated in combined models because the 10-year graft survival probability was lower in patients with C3d-binding dnDSA than in those without dnDSAs or with C1q+/C3d− or non-complement-binding dnDSAs (40% vs. 94%, 100%, and 100%, respectively). Based on the kinetics profile, we favor dnDSA removal or modulation at first confirmed positivity, with treatment intensification guided by dnDSA biological characteristics.

AB - Alloantibody-mediated graft injury is a major cause of kidney dysfunction and loss. The complement-binding ability of de novo donor-specific antibodies (dnDSAs) has been suggested as a prognostic tool to stratify patients for clinical risk. In this study, we analyzed posttransplant kinetics of complement-fixing dnDSAs and their role in antibody-mediated rejection development and graft loss. A total of 114 pediatric nonsensitized recipients of first kidney allograft were periodically monitored for dnDSAs using flow bead assays, followed by C3d and C1q assay in case of positivity. Overall, 39 patients developed dnDSAs, which were C1q+ and C3d+ in 25 and nine patients, respectively. At follow-up, progressive acquisition over time of dnDSA C1q and C3d binding ability, within the same antigenic specificity, was observed, paralleled by an increase in mean fluorescence intensity that correlated with clinical outcome. C3d-fixing dnDSAs were better fit to stratify graft loss risk when the different dnDSA categories were evaluated in combined models because the 10-year graft survival probability was lower in patients with C3d-binding dnDSA than in those without dnDSAs or with C1q+/C3d− or non-complement-binding dnDSAs (40% vs. 94%, 100%, and 100%, respectively). Based on the kinetics profile, we favor dnDSA removal or modulation at first confirmed positivity, with treatment intensification guided by dnDSA biological characteristics.

KW - alloantibody

KW - clinical research/practice

KW - immunobiology

KW - immunosuppression/immune modulation

KW - kidney (allograft) function/dysfunction

KW - kidney transplantation/nephrology

KW - monitoring: immune

KW - rejection: antibody-mediated (ABMR)

UR - http://www.scopus.com/inward/record.url?scp=84976464893&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84976464893&partnerID=8YFLogxK

U2 - 10.1111/ajt.13700

DO - 10.1111/ajt.13700

M3 - Article

VL - 16

SP - 2106

EP - 2116

JO - American Journal of Transplantation

JF - American Journal of Transplantation

SN - 1600-6135

IS - 7

ER -